糖尿病性神经病变是糖尿病常见并发症之一,随着糖尿病患者的增多其发病率也相应增多.本病治疗困难.我们用刺五加治疗糖尿病神经病变,并与细胞激活剂对照观察,现报道如下.1 临床资料1.1 病例选择 1995年1月～1995年12月收住糖尿病患者186例,其中并发糖尿病神经病变112例,占糖尿病患者的60.22%.按自愿原则分为刺五加治疗组66例,辅酶A对照组36例.其一般情况对比见表1. Diabetic neuropathy is one of the common complications of diabetes, with the increase in the incidence of diabetes patients also increased accordingly. The treatment of this disease is difficult .We use Acanthopanax for the treatment of diabetic neuropathy, and cell activation agent control observed, it is reported As follows.1 Clinical data 1.1 Case Selection 186 cases of diabetic patients admitted between January 1995 and December 1995, of which 112 cases of diabetic neuropathy, accounting for 60.22% of patients with diabetes.According to the voluntary principle is divided into Acanthopanax treated group 66 For example, coenzyme A control group of 36 cases of its general situation in contrast to Table 1.